Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders O Devinsky, MR Cilio, H Cross, J Fernandez‐Ruiz, J French, C Hill, ... Epilepsia 55 (6), 791-802, 2014 | 1143 | 2014 |
Molecular targets of cannabidiol in neurological disorders CI Bih, T Chen, AVW Nunn, M Bazelot, M Dallas, BJ Whalley Neurotherapeutics 12 (4), 699-730, 2015 | 607 | 2015 |
Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo NA Jones, AJ Hill, I Smith, SA Bevan, CM Williams, BJ Whalley, ... Journal of Pharmacology and Experimental Therapeutics 332 (2), 569-577, 2010 | 433 | 2010 |
Phytocannabinoids as novel therapeutic agents in CNS disorders AJ Hill, CM Williams, BJ Whalley, GJ Stephens Pharmacology & therapeutics 133 (1), 79-97, 2012 | 416 | 2012 |
Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro … FA Iannotti, CL Hill, A Leo, A Alhusaini, C Soubrane, E Mazzarella, ... ACS chemical neuroscience 5 (11), 1131-1141, 2014 | 400 | 2014 |
Cannabinoids and epilepsy EC Rosenberg, RW Tsien, BJ Whalley, O Devinsky Neurotherapeutics 12 (4), 747-768, 2015 | 339 | 2015 |
Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures NA Jones, SE Glyn, S Akiyama, TDM Hill, AJ Hill, SE Weston, ... Seizure 21 (5), 344-352, 2012 | 316 | 2012 |
Hypericum perforatum: Pharmacokinetic, Mechanism of Action, Tolerability, and Clinical Drug–Drug Interactions E Russo, F Scicchitano, BJ Whalley, C Mazzitello, M Ciriaco, S Esposito, ... Phytotherapy research 28 (5), 643-655, 2014 | 268 | 2014 |
Molecular pharmacology of phytocannabinoids SE Turner, CM Williams, L Iversen, BJ Whalley Phytocannabinoids: unraveling the complex chemistry and pharmacology of …, 2017 | 256 | 2017 |
Cannabidivarin‐rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor‐independent mechanism TDM Hill, MG Cascio, B Romano, M Duncan, RG Pertwee, CM Williams, ... British journal of pharmacology 170 (3), 679-692, 2013 | 234 | 2013 |
Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection EC Rosenberg, PH Patra, BJ Whalley Epilepsy & Behavior 70, 319-327, 2017 | 229 | 2017 |
Pharmacological foundations of cannabis chemovars MA Lewis, EB Russo, KM Smith Planta medica 84 (04), 225-233, 2018 | 210 | 2018 |
The proposed mechanisms of action of CBD in epilepsy RA Gray, BJ Whalley Epileptic Disorders 22, S10-S15, 2020 | 209 | 2020 |
Cannabidivarin is anticonvulsant in mouse and rat AJ Hill, MS Mercier, TDM Hill, SE Glyn, NA Jones, Y Yamasaki, ... British journal of pharmacology 167 (8), 1629-1642, 2012 | 202 | 2012 |
Emergence of a small-world functional network in cultured neurons JH Downes, MW Hammond, D Xydas, MC Spencer, VM Becerra, ... PLoS computational biology 8 (5), e1002522, 2012 | 172 | 2012 |
Δ9‐Tetrahydrocannabivarin suppresses in vitro epileptiform and in vivo seizure activity in adult rats AJ Hill, SE Weston, NA Jones, I Smith, SA Bevan, EM Williamson, ... Epilepsia 51 (8), 1522-1532, 2010 | 154 | 2010 |
Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models PH Patra, M Barker‐Haliski, HS White, BJ Whalley, S Glyn, H Sandhu, ... Epilepsia 60 (2), 303-314, 2019 | 143 | 2019 |
The synaptic vesicle glycoprotein 2A ligand levetiracetam inhibits presynaptic Ca2+ channels through an intracellular pathway C Vogl, S Mochida, C Wolff, BJ Whalley, GJ Stephens Molecular pharmacology 82 (2), 199-208, 2012 | 140 | 2012 |
Cannabinol and cannabidiol exert opposing effects on rat feeding patterns JA Farrimond, BJ Whalley, CM Williams Psychopharmacology 223, 117-129, 2012 | 121 | 2012 |
Medicinal cannabis: is Δ9–tetrahydrocannabinol necessary for all its effects? JD Wilkinson, BJ Whalley, D Baker, G Pryce, A Constanti, S Gibbons, ... Journal of Pharmacy and Pharmacology 55 (12), 1687-1694, 2003 | 119 | 2003 |